neuMirRx issued U.S. patent for “methods for enhancing solubility of compounds
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company’s Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD). The DSMB reported that in order for the study to be 80% powered to detect a p-value of .01, the necessary statistical hurdle under the current
Full Post: Gentium S.p.A. updates on phase 3 trial of Defibrotide for severe veno-occlusive disease
neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled “Methods for Enhancing Solubility of Compounds” which covers novel formulation methods to enhance the solubility of hydrophobic compounds.
The rights to this patent and related proprietary technology, the neuNanoParticle™, have been obtained by neuMirRx Corp through an exclusive license arrangement with Formatech, Inc. of Andover, Massachusetts.
“The proprietary neuNanoParticle™ technology effectively solubilizes pharmaceutical compounds in micellar formulations containing fatty acids and/or fatty alcohols and further results in much higher maximum tolerated doses (MTD),” said Ben Isaacs, Ph.D., CEO, neuMirRx Corp. “In addition to addressing significant excipient related safety issues, the technology also delivers drug formulations that are compatible with parenteral (both liquid and lyophilized), oral, pulmonary and topical routes of administration,” he added.
“We are applying this novel technology to several commercially successful drugs in markets that welcome and support safer, more effective drug product formulation. This includes drugs such as Taxotere?, Taxol?, Diprivan? and Cyclosporin,” said Dr. Issacs. “Our acquisition of this technology demonstrates our company’s continuing mission to chart a new course in drug delivery for human healthcare,” he added.
The Andover, Massachusetts based company, neuMirRx Corp, seeks to apply this patented technology to approved pharmaceutical products to develop and commercialize Qualiceuticals™ - next generation quality pharmaceutical products with enhanced safety and efficacy profiles. neuMirRx also seeks to in-license and/or partner to extend the neuNanoParticle™ advantage to novel pharmaceutical compounds or new chemical entities.
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.” The patent includes claims to pharmaceutical compositions containing reovirus. “This U.S. patent expands and strengthens our proprietary position for REOLYSIN(R),” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “The
Full Post: Oncolytics Biotech issued new U.S. patent “Reovirus for the Treatment of Neoplasia”
The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract. It is the third international patent, from many patents pending, that the technology has been awarded based on BIO-tract’s ability to protect sensitive ingredients like probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract. Steve Moger,
Full Post: Nutraceutix issued Australian patent
Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company’s method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain. Probuphine is Titan’s novel, subcutaneous implant formulation in development
Full Post: Titan Pharmaceuticals updates on Probuphine patent application
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United
Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries
Gel Technologies Ltd today announced the successful completion of an investment round of $9 million. The funding will be used to accelerate Sol-Gel’s robust pipeline of innovative topical products for the dermatology market. The company’s pipeline includes a new generation of anti-acne kits that target the $1 billion acne therapy market. “Even in the current
Full Post: Gel Technologies raises $9 million